» Articles » PMID: 32123080

Immunotoxin SS1P is Rapidly Removed by Proximal Tubule Cells of Kidney, Whose Damage Contributes to Albumin Loss in Urine

Overview
Specialty Science
Date 2020 Mar 4
PMID 32123080
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Recombinant immunotoxins (RITs) are chimeric proteins composed of an Fv and a protein toxin being developed for cancer treatment. The Fv brings the toxin to the cancer cell, but most of the RITs do not reach the tumor and are removed by other organs. To identify cells responsible for RIT removal, and the pathway by which RITs reach these cells, we studied SS1P, a 63-kDa RIT that targets mesothelin-expressing tumors and has a short serum half-life. The major organs that remove RIT were identified by live mouse imaging of RIT labeled with FNIR-Z-759. Cells responsible for SS1P removal were identified by immunohistochemistry and intravital two-photon microscopy of kidneys of rats. The primary organ of SS1P removal is kidney followed by liver. In the kidney, SS1P passes through the glomerulus, is taken up by proximal tubular cells, and transferred to lysosomes. In the liver, macrophages are involved in removal. The short half-life of SS1P is due to its very rapid filtration by the kidney followed by degradation in proximal tubular cells of the kidney. In mice treated with SS1P, proximal tubular cells are damaged and albumin in the urine is increased. SS1P uptake by kidney is reduced by coadministration of l-lysine. Our data suggests that l-lysine administration to humans might prevent SS1P-mediated kidney damage, reduce albumin loss in urine, and alleviate capillary leak syndrome.

Citing Articles

Expanding the Therapeutic Window of EGFR-Targeted PE24 Immunotoxin for EGFR-Overexpressing Cancers by Tailoring the EGFR Binding Affinity.

Jun S, Kim D, Kim Y Int J Mol Sci. 2022; 23(24).

PMID: 36555466 PMC: 9779439. DOI: 10.3390/ijms232415820.


Systemic immune changes accompany combination treatment with immunotoxin LMB-100 and nab-paclitaxel.

Pegna G, Lee M, Peer C, Ahmad M, Venzon D, Yu Y Cancer Med. 2022; 12(4):4236-4249.

PMID: 36208017 PMC: 9972172. DOI: 10.1002/cam4.5290.


Podocytes are lost from glomeruli before completing apoptosis.

Yamamoto K, Okabe M, Tanaka K, Yokoo T, Pastan I, Araoka T Am J Physiol Renal Physiol. 2022; 323(5):F515-F526.

PMID: 36049065 PMC: 9602714. DOI: 10.1152/ajprenal.00080.2022.


Strategies to mitigate the on- and off-target toxicities of recombinant immunotoxins: an antibody engineering perspective.

Li M, Mei S, Yang Y, Shen Y, Chen L Antib Ther. 2022; 5(3):164-176.

PMID: 35928456 PMC: 9344849. DOI: 10.1093/abt/tbac014.


Albumin Expands Albumin Reabsorption Capacity in Proximal Tubule Epithelial Cells through a Positive Feedback Loop between AKT and Megalin.

Silva-Aguiar R, Peruchetti D, Florentino L, Takiya C, Marzolo M, Dias W Int J Mol Sci. 2022; 23(2).

PMID: 35055044 PMC: 8776186. DOI: 10.3390/ijms23020848.


References
1.
Kobayashi H, Yoo T, Kim I, Kim M, Le N, Webber K . L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment. Cancer Res. 1996; 56(16):3788-95. View

2.
Jeong G, Lee K, Lee I, Oh J, Kim D, Shin J . Incidence of Capillary Leak Syndrome as an Adverse Effect of Drugs in Cancer Patients: A Systematic Review and Meta-Analysis. J Clin Med. 2019; 8(2). PMC: 6406478. DOI: 10.3390/jcm8020143. View

3.
Kreitman R, Tallman M, Robak T, Coutre S, Wilson W, Stetler-Stevenson M . Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012; 30(15):1822-8. PMC: 3383181. DOI: 10.1200/JCO.2011.38.1756. View

4.
Russo L, Sandoval R, McKee M, Osicka T, Collins A, Brown D . The normal kidney filters nephrotic levels of albumin retrieved by proximal tubule cells: retrieval is disrupted in nephrotic states. Kidney Int. 2007; 71(6):504-13. DOI: 10.1038/sj.ki.5002041. View

5.
Weldon J, Xiang L, Zhang J, Beers R, Walker D, Onda M . A recombinant immunotoxin against the tumor-associated antigen mesothelin reengineered for high activity, low off-target toxicity, and reduced antigenicity. Mol Cancer Ther. 2012; 12(1):48-57. PMC: 3546136. DOI: 10.1158/1535-7163.MCT-12-0336. View